The invention relates to a method for the stabilization of a polysaccharide (hyaluronic acid) with a biomolecule—amino acid—through crosslinking, to generate a bionic hydrogel based on physiological building blocks for applications in regenerative medicine. The designed biosimilar hydrogel is intended to be used in regenerative medicine for the purpose of regenerate, rejuvenate and/or restore the structure or function of impaired or damaged tissues, and to promote healing. The manufacture method is composed of a single step that includes mixing L-lysine and hyaluronic acid sodium salt in an aqueous saline solution with either EDC/NHS as coupling agent.

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

An injectable medical composition includes an acrylate and a solvent. The composition has a first viscosity at temperatures below body temperature and a second viscosity at body temperature. The first viscosity is lower than the second viscosity.

An injectable medical composition includes an acrylate and a solvent. The composition has a first viscosity at temperatures below body temperature and a second viscosity at body temperature. The first viscosity is lower than the second viscosity.

The present invention relates to a process for the preparation of crosslinked hyaluronic acid butyrate or crosslinked hyaluronic acid butyrate-formate or an acceptable salt thereof, wherein the process comprises the crosslinking reaction of hyaluronic acid butyrate or hyaluronic acid butyrate-formate or a pharmaceutically acceptable salt thereof in an organic solvent with a carboxyl activating reagent, characterized in that the hyaluronic acid butyrate or hyaluronic acid butyrate-formate or pharmaceutically acceptable salt thereof is a mixture of a high-molecular-weight polysaccharide and a low-molecular-weight polysaccharide.

The present invention relates to a process for the preparation of crosslinked hyaluronic acid butyrate or crosslinked hyaluronic acid butyrate-formate or an acceptable salt thereof, wherein the process comprises the crosslinking reaction of hyaluronic acid butyrate or hyaluronic acid butyrate-formate or a pharmaceutically acceptable salt thereof in an organic solvent with a carboxyl activating reagent, characterized in that the hyaluronic acid butyrate or hyaluronic acid butyrate-formate or pharmaceutically acceptable salt thereof is a mixture of a high-molecular-weight polysaccharide and a low-molecular-weight polysaccharide.

The present invention concerns a three-dimensional bipolymeric matrix deploying biological and biomechanical activity, able to neutralize the various physiopathological parameters involved in the development and worsening of skin lesions and/or sores, combining: a first polymeric network comprising first colloids (Col-1) bonded non-covalently to an unsulfated crosslinked polysaccharide; and a second polymeric network comprising second colloids (Col-2) bonded covalently or non-covalently to a sulfated polysaccharide.

The present invention concerns a three-dimensional bipolymeric matrix deploying biological and biomechanical activity, able to neutralize the various physiopathological parameters involved in the development and worsening of skin lesions and/or sores, combining: a first polymeric network comprising first colloids (Col-1) bonded non-covalently to an unsulfated crosslinked polysaccharide; and a second polymeric network comprising second colloids (Col-2) bonded covalently or non-covalently to a sulfated polysaccharide.

The present invention relates to a hyperbranched polyglycerol polyglycidyl ether having a molecular weight from 750 to 15.000 Da; and an epoxy equivalent weight from 183 to 7.000 g/eq. It also relates to a crosslinked polysaccharide obtainable by crosslinking the polysaccharide with the hyperbranched polyglycerol polyglycidyl ether. The present invention also relates to processes for their preparation and their uses in therapy, cosmetic, agriculture and food field.